For the forecasted year 2022-2030, the Germany breast cancer therapeutics market is expected to see growth from $666 Mn in 2022 to $1,546 Mn in 2030 with a CAGR of 11.1%. Introduction of new screening programs and government initiatives to increase awareness of breast cancer and major market drivers in Germany. The market is segmented by therapy, by cancer type, and by distribution channel. Some of the leading companies in Germany breast cancer therapeutics market are Janssen, GSK, and Merck & Co., Inc.
Germany Sanfilippo Syndrome (MPS-III) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Sanfilippo Syndrome (MPS-III) Therapeutics is growing rapidly as a result of increase in research and development activities, patient support and advocacy programmes, launch of new emerging therapies, increase in healthcare spending globally. Phoenix Nest Inc, Allievex Corp, Amicus Therapeutics Inc, ArmaGen Inc, Esteve Pharmaceuticals SA, JCR Pharmaceuticals Co Ltd, M6P Therapeutics, Orchard Therapeutics Plc, Seelos Therapeutics, Inc., and BioStrategies LC are top key players operating in global Sanfilippo Syndrome (MPS-III) Therapeutics market.
Germany Cystic Fibrosis (CF) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Cystic fibrosis (abbreviated CF) is a genetic disorder that causes mucus to build up in certain organs of the body, particularly the lungs and pancreas, resulting in breathing problems, respiratory infections and faulty digestion. The increasing prevalence of Cystic Fibrosis (CF) coupled with the rising treatment rate is one of the key factors anticipated to propel the demand for cystic fibrosis therapeutics over the forecast period. The key players are consistently involved in the development of new or combination of products to treat cystic fibrosis. Investment in the R&D is one of the strategic measures to beat the competition. The key players in this market are AbbVie Inc.; F. Hoffmann-La Roche Ltd; Gilead; Novartis AG; Vertex Pharmaceuticals Inc.; AIT (Advanced Inhalation Therapies); Alaxia; Teva Pharmaceutical Industries Ltd; Merck & Co. Inc.; Alcresta Therapeutics Inc.; Allergan; and AstraZeneca.
Germany Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A number of factors, including the rising prevalence of non-alcoholic steatohepatitis, the rising incidence of chronic illnesses linked to it, the rising adoption of sedentary lifestyles, the rising awareness of health issues, etc., have contributed to the growth of the non-alcoholic steatohepatitis market over the past few years. Major global players in Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market are Intercept Pharmaceuticals, Inc. Novartis AG,Siemens Healthineers AG, AstraZeneca PLC, Galectin Therapeutics Inc., GENFIT S.A., Madrigal Pharmaceuticals, Inc., Inventiva S.A., ONE WAY LIVER, S.L., Galmed Pharmaceuticals Ltd., Cirius Therapeutics, Prometheus Laboratories Inc., BioPredictive.
This report presents a strategic analysis of the Germany In Vitro Fertilisation (IVF) Service Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Germany In Vitro Fertilisation (IVF) Service Market, offering unmatched value, accuracy and expert insights.
This report presents a strategic analysis of the Germany Pain Management Devices Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Germany Pain Management Devices Market, offering unmatched value, accuracy and expert insights.
Germany Lipid Disorder Therapeutics Market was valued at $22.2 Mn in 2023 and is predicted to grow at a CAGR of 13.13% from 2023 to 2030, to $52.7 Mn by 2030. Germany Lipid Disorder Therapeutics Market is growing due to the Growing Geriatric Population, Advancements in Lipid-Lowering Therapies, Government Initiatives, and Reimbursement Policies. The industry is primarily dominated by players such as Sanofi, Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Viatris, AstraZeneca PLC, and Dr. Reddys Laboratories Ltd.
Germany's Cancer Pain Management market is projected to grow from $238.63 Mn in 2022 to $314.23 Mn by 2030, registering a CAGR of 3.5% during the forecast period of 2022 - 2030. The main factors driving the growth would be an increase in cancer cases and government initiatives. The market is segmented by drug type and by disease. Some of the major players include Grunenthal Pharma (DEU), Teva Pharmaceuticals, Pfizer, Abbott, and GW Pharma.
Germany's Chronic Obstructive Pulmonary Disease (COPD) therapeutics market was valued at $668 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.3% from 2022-30 and will reach $1010 Mn in 2030. One of the main reasons propelling the growth of this market is the increased prevalence rate and government initiative. The market is segmented by Drug class and by distribution channel. Some key players in this market are Kaia Health, Grifols, Riemser, Adamis Pharmaceuticals Corporation, Almirall, Astellas Pharma, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Novartis, Pfizer, Teva Germany Limited, and others.
This report presents a strategic analysis of the Germany Sleep Disorders Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Germany Sleep Disorders Market, offering unmatched value, accuracy and expert insights.
Germany Genomic Diagnostics Market was valued at $1,194.99 Mn in 2023 and is predicted to grow at a CAGR of 14.7% from 2023 to 2030, to $3,121.10 Mn by 2030. The key drivers of this industry include the rising prevalence of chronic diseases, personalized medicine and companion diagnostics, and technological advancements. The industry is primarily dominated by Illumina, 23andMe, Myriad Genetics, and Amgen among others.
Germany Contact Lenses Market was valued at $627.32 Mn in 2023 and is predicted to grow at a CAGR of 7.1% from 2023 to 2030, to $1,013.95 Mn by 2030. The key drivers of this industry include the high prevalence of refractive errors, increasing demand for convenience, technological advancements, and rising disposable income. The industry is primarily dominated by Bausch and Lomb, CooperVision, Alcon Vision, and Essilor among others.
The Germany Electronic Health Record (EHR) market size was valued at $1.02 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 2.2% from 2022 to 2030 and will reach $1.23 Bn in 2030. Germany's EHR market will grow due to a growing desire to centralize and streamline healthcare administration. The key market players are Siemens Healthineers, Cerner, Allgeier, CompuGroup Medical, and others.
Germany Chronic Myelogenous Leukemia Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Chronic granulocytic leukemia, often known as chronic myelogenous leukemia (CML), is a slowly progressive blood and bone marrow condition that most frequently affects adults in or after middle age and very infrequently affects children. Because of the rising incidence of the condition, the introduction of novel medications, and the expanding use of personalized medicine, the market for CML treatments is anticipated to expand gradually in the years to come. Bristol-Myers Squibb Co., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Mylan NV, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH, and Sanofi are a few of the businesses that are now dominating the industry.
This report presents a strategic analysis of the Germany Obesity Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Germany Obesity Drugs Market, offering unmatched value, accuracy and expert insights.
Germany CDKL5 deficiency disorder Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for CDKL5 deficiency disorder is expanding as a result of increase in global prevalence of CDKL5 deficiency disorder and increase in awareness about neurological diseases. In addition, high expenditure on healthcare and genetic testing, growing demand for targeted therapies, increase in R&D spending for the discovery of novel pharmaceuticals are other reasons . This demand is fueling the development of better pharmaceuticals and other treatment methods for the accurate treatment of CDKL5 deficiency disorder. Some of the key players in the global CDKL5 deficiency disorder market include Marinus pharmaceuticals, REGENXBIO, Zogenix, PTC therapeutics and Ovid therapeutics/ Takeda
The Germany Bio-implant Market was valued at $2379 Mn in 2023 and is predicted to grow at a CAGR of 4.1% from 2023 to 2030, to $3151.7 Mn by 2030. The Germany Bio-implant Market is growing due to Technological Advancements, Healthcare Expenditure, and Increasing Surgical Procedures. The market is primarily dominated by players such as B. Braun Melsungen AG, Biotronik SE & Co. KG, Zimmer Biomet Holdings, Inc., Otto Bock HealthCare GmbH, Heraeus Holding GmbH, and Stryker Corporation.
The Germany Dental Caries Detectors Market was valued at $8.4 Mn in 2023 and is predicted to grow at a CAGR of 7.1% from 2023 to 2030, to $13.5 Mn by 2030. Germany Dental Caries Detectors Market is growing due to Increasing Prevalence of Dental Caries, Government Initiatives and Funding, and Advanced imaging and diagnostic. The market is primarily dominated by players such as Elmex, Meridol, Blend-a-med, Sirona Dental Systems, Dentsply Sirona, KaVo Kerr, Ivoclar Vivadent, Planmeca Oy, Adec Technologies, 3M ESPE, Morita Corporation, Woodpecker Medical Instruments Co., Softdent.
The Germany Clinical Nutrition for Diabetes Care Market was valued at $78.69 Mn in 2023 and is predicted to grow at a CAGR of 2.98% from 2023 to 2030, to $96.65 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are Nestle Health Science, Fresenius Kabi, Baxter International, and Novo Nordisk among others.
The Germany Pharmacy Automation Device Market was valued at $201.3 Mn in 2023 and is predicted to grow at a CAGR of 8.1% from 2023 to 2030, to $347.2 Mn by 2030. Germany Pharmacy Automation Device Market is growing due to Increasing Healthcare Expenditure, Rising Medication Errors, Technological Advancements. The market is primarily dominated by players such as Swisslog Healthcare, Becton, Dickinson and Amerisource Bergen Corporation, Accu-Chart Plus Healthcare Systems, Omnicell, Inc., McKesson Corporation.
The Germany Cardiac Pacemakers Market was valued at $148.12 Mn in 2023 and is predicted to grow at a CAGR of 1.4% from 2023 to 2030, to $163.26 Mn by 2030. The key drivers of this industry include the prevalence of cardiovascular disease, the aging population, and technological advancements. The industry is primarily dominated by players such as Abbott Laboratories, Biotronik, Boston Scientific, and Medtronic among others.
The Germany Exosome Research Market was valued at $6.2 Mn in 2023 and is projected to grow at a CAGR of 14.2% from 2023 to 2023, to $15.7 Mn by 2030. The key drivers of this industry are increasing prevalence and incidences of cancer and various auto-immune diseases, rising healthcare expenditure for better health services, growing R&D activities associated with exosome research, technological advancements in exosome isolation and analytical procedures, and increasing advanced applications of exosomes. The industry is primarily dominated by players such as Thermo Fisher Scientific, NanoSomix, NX Pharmagen, Malvern Instruments, Capricor Therapeutic among others.
The Germany Clinical Nutrition for Cancer Care Market was valued at $206.1 Mn in 2023 and is predicted to grow at a CAGR of 3.24% from 2023 to 2030, to $257.6 Mn by 2030. The key drivers of the market include the increasing prevalence of cancer, increased awareness and education, and increasing healthcare expenditure. The prominent players of the Germany Clinical Nutrition for Cancer Care Market are Fresenius Kabi, Baxter Deutschland GmbH, Dr. Franz Schneider GmbH & Co. KG, Nutricia GmbH, and B. Braun Melsungen AG, among others.
The Germany Gram-Negative Infection Therapeutics Market was valued at $544.4 Mn in 2023 and is predicted to grow at a CAGR of 4.1% from 2023 to 2030 to $721.3 Mn by 2030. Key market growth drivers include increasing prevalence, technological advancements, and growing awareness of antimicrobial resistance (AMR). Major players in this market include Pfizer Inc., Nektar Therapeutics, and other notable companies.
The Germany Home Infusion Therapy Market was valued at $1316.1 Mn in 2023 and is predicted to grow at a CAGR of 6.3% from 2023 to 2030, to $2018.5 Mn by 2030. The key drivers of the market include rising prevalence of chronic diseases, expanding geriatric population, and technological advancements. The prominent players of the Germany Home Infusion Therapy Market are Option Care Health, Baxter International, ICU Medical (Smiths Medical), Becton, Dickinson and Company (BD), and Fresenius Kabi, among others.